Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 Results

Fintel reports that Accelmed Partners II L.P. has filed a 13D form with the SEC disclosing ownership of 4,042,657 shares of Neuropace, Inc. (NPCE). This represents 16.2% of the company. Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming…#compared #prior #representing #period #neuropace #accelmed #expenses #expense #ownership #sentiment
Source: Reuters: Health - Category: Consumer Health News Source Type: news